Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
Status:
Recruiting
Trial end date:
2033-10-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to learn about the safety and effectiveness of the combination of
tazemetostat pills in combination with mosunetuzumab injections for people with follicular
lymphoma who haven't received treatment before. The investigators hypothesize that
tazemetostat with mosunetuzumab has the potential to increase the efficacy of the product
without compromising the safety.
Tazemetostat is a drug that inhibits EZH2, an enzyme known to drive the development of B-cell
lymphomas, and inhibiting it appears to have many effects that slow down lymphoma growth and
enhance the immune system's ability to fight it. Tazemetostat is FDA-approved in previously
treated follicular lymphoma and currently undergoing study in other lymphomas.
Mosunetuzumab is a bispecific antibody therapy that is a therapeutic strategy that uses the
immune system to fight lymphoma, called immunotherapy. Bispecific antibodies have two ends:
one attaches to T cells in the immune system and the other attaches to lymphoma cells,
helping guide our immune system to attack the cancer. Mosunetuzumab has been studied in
follicular lymphoma that has previously been treated, with positive results. Mosunetuzumab is
approved by the FDA to be given intravenously (directly into a vein) but is not yet approved
by the FDA is not yet approved as an injection under the skin, which is how it is given in
this study. They have not yet been studied in combination.